Premium
miR‐138 mediates sorafenib‐induced cell survival and is associated with poor prognosis in cholangiocarcinoma cells
Author(s) -
Zheng Yingjie,
Zhang Jingyu,
Ye Bin
Publication year - 2020
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/1440-1681.13205
Subject(s) - sorafenib , sox4 , cancer research , malignancy , viability assay , apoptosis , metastasis , cell , biology , microrna , medicine , oncology , cancer , hepatocellular carcinoma , gene , gene expression , promoter , biochemistry , genetics
Cholangiocarcinoma is an aggressive malignancy with rapid invasion, metastasis and poor prognosis, however, the mechanism mediating its cholangiocarcinoma development needs further investigation. Here, we demonstrate that decreased miR‐138 in tumor tissues is related to the poor prognosis in patients, and that miR‐138 mediates sorafenib‐induced cell survival in cholangiocarcinoma cells. Moreover, miR‐138 negatively regulates SOX4 expression by specifically targeting its 3′ untranslated region (3′ UTR). As per our results, overexpression of SOX4 reversed sorafenib‐induced changes in cell viability and apoptosis. Furthermore, the elevated levels of SOX4 in the tumor tissues that correlated with poor prognosis. Overall, the present study reveals that miR‐138/SOX4 is involved in sorafinib‐mediated cell survival in cholangiocarcinoma cells, and is associated with poor prognosis.